Supernus Pharmaceuticals (SUPN) Receivables - Net (2011 - 2026)

Supernus Pharmaceuticals (SUPN) has 16 years of Receivables - Net data on file, last reported at $182.2 million in Q1 2026.

• Receivables - Net for Q1 2026 came in at $182.2 million, up 25.09% year-over-year; the trailing twelve-month figure through Mar 2026 was $182.2 million (up 25.09% YoY), and the FY2025 annual result was $187.8 million, up 32.18% from the prior year.
• Receivables - Net eased to $182.2 million in Q1 2026 per SUPN's latest filing, from $187.8 million in the prior quarter.
• Over five years, Receivables - Net peaked at $187.8 million in Q4 2025 and troughed at $136.6 million in Q2 2023.
• A 5-year average of $153.8 million and a median of $145.6 million in 2025 frame the typical range for Receivables - Net.
• The sharpest annual moves came in 2023 and 2025: Receivables - Net declined 13.61% in 2023, then surged 32.18% in 2025.
• A 5-year view of Receivables - Net shows it stood at $165.5 million in 2022, then dropped by 12.9% to $144.2 million in 2023, then dropped by 1.44% to $142.1 million in 2024, then jumped by 32.18% to $187.8 million in 2025, then decreased by 2.99% to $182.2 million in 2026.
• Business Quant data shows SUPN's Receivables - Net at $182.2 million in Q1 2026, $187.8 million in Q4 2025, and $171.3 million in Q3 2025.